Ship 40 to 50 NovaSeq X instruments
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2023
- Due
- 31 Mar 2023
- Delivered
- Q1 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“We plan to ship 40 to 50 instruments in Q1 and over 300 instruments in 2023.”
What we found
Evidence strength A What the grades mean
The April 2023 8-K says Illumina shipped 67 NovaSeq X instruments in Q1 2023, above its plan of 40 to 50.
-
A Illumina, Inc. 8-K filed 2023-04-25
“We shipped 67 NovaSeq X instruments in the first quarter, exceeding our plan.” ✓ confirmed on the page
Market reaction: the shares moved -10.7% against the S&P 500 over the three sessions around the disclosure (24 Apr 2023 to 27 Apr 2023). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Delivery
- Indicative materiality
- Medium rules
- Action
- Ship
- Deliverable
- NovaSeq X instrument shipments
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Illumina, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-ILMN-005580 · Corrections policy